ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
4,735,600
4,131,200
3,551,100
3,084,000
2,604,047
Cost of Revenue
377,000
374,300
454,200
258,000
233,089
Gross Profit
4,358,600
3,756,900
3,096,900
2,826,000
2,370,958
Operating Expenses
Research Development
822,000
730,400
878,400
757,000
709,472
Selling General and Administrative
1,198,800
1,111,800
1,094,400
954,000
862,595
Total Operating Expenses
2,336,500
2,162,300
2,292,900
2,033,000
1,688,651
Operating Income or Loss
2,022,100
1,594,600
804,000
793,000
682,307
Interest Expense
80,600
98,200
98,400
97,000
47,744
Total Other Income/Expenses Net
-397,600
-1,254,200
-157,800
-120,000
-136,421
Income Before Tax
1,543,900
242,200
547,800
576,000
498,142
Income Tax Expense
73,600
164,600
104,500
177,000
353,757
Income from Continuing Operations
1,470,300
77,600
443,300
399,000
144,385
Net Income
1,470,300
77,600
443,300
399,000
144,385
Net Income available to common shareholders
1,470,300
77,600
443,300
399,000
144,385
Reported EPS
Basic
-
0.35
1.98
1.78
0.68
Diluted
-
0.35
1.97
1.76
0.67
Weighted average shares outstanding
Basic
-
222,700
223,900
224,000
213,431
Diluted
-
224,500
225,400
227,000
215,933
EBITDA
-
660,500
966,300
995,000
662,470